1-(diphenylmethyl)-4-ethylpiperazine | 48187-94-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(diphenylmethyl)-4-ethylpiperazine
• 英文别名: N¹-Ethyl-N⁴-benzhydryl-piperazin；1-benzhydryl-4-ethyl-piperazine；1-ethyl-4-benzhydryl-piperazine；1-Aethyl-4-benzhydryl-piperazin；1-Benzhydryl-4-ethylpiperazine
• CAS: 48187-94-6
• 化学式: C₁₉H₂₄N₂
• 分子量: 280.413
• InChiKey: CYNGTSJHMUHWKA-UHFFFAOYSA-N

物化性质

• 熔点：
  51 °C
• 沸点：
  378.7±32.0 °C(Predicted)
• 密度：
  1.045±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-bromo-8-hydroxypsoralen 、 1-(diphenylmethyl)-4-ethylpiperazine 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 0.5h， 以73%的产率得到4-bromo-9-(2-(4-benzhydrylpiperazin-1-yl)ethoxy)-7H-furo[3,2-g]chromen-7-one
  参考文献：
  名称：

  Synthesis and vasorelaxation evaluation of novel biphenyl–furocoumarin derivatives

  摘要：

  A series of novel biphenyl-furocoumarin derivatives were synthesized and evaluated for their vasorelaxant activities in vitro against rat mesenteric artery, basilar artery, and renal artery ring models pre-contracted by high KCl. The results showed that compounds 12b, 13b, 13d, 14b, and 14d exhibited good broad spectrum vasorelaxant activities on three kinds of rat artery ring models compared to imperatorin. Noteworthy, most of the compounds had potent good selectivity against mesenteric artery in which compound 14c exhibited highest vasodilation activity (pEC(50) = 6.44, E (max) = 105.8 %). These were suggested that the introduction of biphenyl in imperatorin was useful to improve vasodilation activities. The preliminary structure-activity relationships studies revealed that larger halogen substituent R (1) on phenyl ring and smaller nitrogenous base R (2) were favorable for vasorelaxant activities. In addition, the CoMFA model showed acceptable correlative and predictive abilities (r (2) = 0.875, q (2) = 0.502).

  DOI：

  10.1007/s00044-014-1303-7
• 作为产物：
  描述：

  二苯甲基哌嗪 、 碘乙烷 在 碳酸氢钠 作用下， 以 苯 为溶剂， 以44.73%的产率得到1-(diphenylmethyl)-4-ethylpiperazine
  参考文献：
  名称：

  Percutaneous absorption of cyclizine and its alkyl analogues

  摘要：

  Cyclizine (I) alkyl analogues (II-IV) were synthesized and their skin permeation parameters evaluated in vitro. It was hoped that these compounds would possess physicochemical properties more favourable for percutaneous delivery than (I). The identification and levels of purity for the compounds were confirmed by mass spectrometry (MS), nuclear magnetic resonance (NMR) spectrometry, and infrared spectrometry (IR) while melting points were determined by an electrothermal digital Bupsilonchi melting point apparatus. Aqueous solubilities (25 degrees C) and partition coefficients were determined and in vitro permeation studies were performed in buffer (37 degrees C) at pH 7.4 over a period of 24 h, using Franz diffusion cells fitted with human epidermal membranes. Generally, the analogues were more lipophilic, but nevertheless possessed higher aqueous solubilities as compared to (I). (II) and (IV) exhibited two- to three-fold increase in aqueous solubility and their melting temperatures dropped by more than 55 degrees C. Compound (III) had similar aqueous solubility to (I), but its melting point dropped by about 35 degrees C. Measured steady-state fluxes indicated that (II) is a far better penetrant (J=6.95 microg/cm(2)/h) of human epidermis than (I). Although fluxes of (III) and (IV) drop off markedly from that of (II), they remained above the flux of (I), which is (0.132 microg/cm(2)/h). In conclusion, (II) was the best skin permeant and also exhibited the highest aqueous solubility and lowest level of crystallinity as compared to (I) and other analogues. (III) and (IV) were more lipophilic. The overall permeation data of this series indicated that the more water-soluble and the lowest melting point compound was the best skin permeant.

  DOI：

  10.1016/j.ejps.2004.11.001

文献信息

• Glycine transporter-1 inhibitors
  申请人：Hitchcock Stephen

  公开号：US20080004289A1

  公开（公告）日：2008-01-03

  The present invention provides compounds that are glycine transporter 1 (hereinafter referred to as GlyT-1) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of GlyT1 such as cognitive disorders associated with Schizophrenia, ADHD (attention deficit hyperactivity disorder), MCI (mild cognitive impairment), and the like. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本发明提供了一种甘氨酸转运蛋白1（以下简称为GlyT-1）抑制剂的化合物，因此可用于治疗通过抑制GlyT1可治疗的疾病，如与精神分裂症、注意力缺陷多动障碍（ADHD）、轻度认知障碍（MCI）等相关的认知障碍。还提供了含有这种化合物的药物组合物以及制备这种化合物的方法。
• Therapeutic Compounds: Pyridine as Scaffold
  申请人：Amin Kosrat

  公开号：US20070225292A1

  公开（公告）日：2007-09-27

  Compounds of formula I or pharmaceutically acceptable salts thereof: wherein R 1 , R 2 , R 3 , R 4 , n and A are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

  式I的化合物或其药学上可接受的盐：其中R1，R2，R3，R4，n和A的定义如规范中所述，以及包括该化合物的盐和制备的药物组合物。它们在治疗中有用，特别是在疼痛管理方面。
• T-type calcium channel blockers
  申请人：Masuda Yukinori

  公开号：US20070010490A1

  公开（公告）日：2007-01-11

  There is provided a T-type calcium channel blocker that is optically active 1,4-dihydropyridine compound, a pharmaceutically acceptable salt thereof or a solvate thereof, of formula (1) wherein R 1 and R 2 are independently of each other C 1-6 alkyl group or R 1 and R 2 together form —CR 5 R 6 —CR 7 R 8 —, —CR 5 R 6 —CR 7 R 8 —CR 9 R 10 — or —CR 5 R 6 —CR 7 R 8 —CR 9 R 10 —CR 11 R 12 —, etc., X 1 and X 2 are independently of each other O or NR 13 , Ar is optionally substituted phenyl group, etc., R a and R b are independently of each other C 1-6 alkyl group, -L 2 -NR 16 R 17 , CH 2 O-L 2 -NR 16 R 17 , CN, -L 2 -N(CH 2 CH 2 ) 2 NR 16 or NR 16 R 17 , etc., Y is C 1-20 alkyl group, -L 3 -NR 18 R 19 and * is absolute configuration of R.

  提供了一种T型钙离子通道阻滞剂，其为光学活性的1,4-二氢吡啶化合物，其药学上可接受的盐或溶剂，其化学式为(1)，其中R1和R2是独立的C1-6烷基或R1和R2一起形成—CR5R6—CR7R8—、—CR5R6—CR7R8—CR9R10—或—CR5R6—CR7R8—CR9R10—CR11R12—等，X1和X2是独立的O或NR13，Ar是可选的取代苯基，Ra和Rb是独立的C1-6烷基、-L2-NR16R17、CH2O-L2-NR16R17、CN、-L2-N(CH2CH2)2NR16或NR16R17等，Y是C1-20烷基、-L3-NR18R19，*是R的绝对构型。
• Histamine Antagonists. II.¹ Unsymmetrical 1,4-Disubstituted Piperazines
  作者：K. E. Hamlin、Arthur W. Weston、Francis E. Fischer、R. J. Michaels

  DOI：10.1021/ja01176a038

  日期：1949.8
• PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS
  申请人：NYMOX CORPORATION

  公开号：EP0983222B1

  公开（公告）日：2007-11-28